NCT00091858已完成3 期
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 1,000
- 主要终点
- Occurrences of red blood cell transfusion
研究概览
简要总结
The purpose of this study is to evaluate the efficacy of darbepoetin alfa versus placebo in reducing the occurrences of red blood cell transfusions in subjects with anemia of cancer who are not receiving chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •subjects with non-myeloid malignancies
- •anemia due to cancer
- •ECOG status 0 to 2
- •greater than or equal to 4-month expectancy
- •greater than or equal to 18 years and of legal age for informed consent
- •screening hemoglobin concentration less than or equal to 11.0g/dL
- •adequate serum folate and vitamin B12
- •adequate renal and liver function
- •written informed consent
排除标准
- •subjects currently receiving or planned to receive cytotoxic chemotherapy or myelosuppressive radiotherapy during the study or within 4 weeks before randomization
- •in complete remission, as determined by the investigator
- •subjects who have other diagnoses not related to the cancer which cause anemia (eg. gastrointestinal bleeding, renal disease, etc)
- •documented history of pure red cell aplasia
- •Known history of seizure disorder
- •cardiac condition: uncontrolled angina, congestive heart failure, known ejection fraction less than 40%, or uncontrolled cardiac arrhythmia
- •uncontrolled hypertension
- •clinically significant systemic infection or chronic inflammatory disease present at the time of randomization
- •iron deficiency
- •known positive test for HIV infection
- •previously suspected of or confirmed to have neutralizing antibodies to rHuEPO or darbepoetin alfa
- •received rHuEPO or darbepoetin alfa therapy within 4 weeks of randomization
- •less than 30 days since receipt of any investigational drug or device that is not approved by the applicable regulatory authority
- •pregnant or breast feeding
- •subject of reproductive potential who is not using adequate contraceptive precautions
- •known hypersensitivity to mammalian-derived product or any other ingredients in the investigational product
- •previously randomized into this study
- •concerns for subject's compliance with the protocol procedures
研究组 & 干预措施
Darbepoetin alfa 6.75 mcg/kg Q4W
Experimental
干预措施: Darbepoetin Alfa (Drug)
Placebo Q4W
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Occurrences of red blood cell transfusion
时间窗: from study day 29 (week 5) to week 17
次要结局
- Incidence of first red blood cell transfusion(from week 5 (study day 29) to week 17 (study day 119))
- Change in hemoglobin concentration measured(from baseline (study day 1) to EOTP)
- Adverse events and serious adverse events(throughout study for subjects who received at least 1 dose of investigational product)
- Survival(deaths on study and deaths in long-term follow-up period for subjects who received at least 1 dose of investigational product)
- Incidence, if any, of neutralizing antibody formation to investigational product(throughout study for subjects who received at least 1 dose of investigational product)
研究者
相似试验
已完成
3 期
Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)MDSNCT01362140Amgen147
已完成
3 期
Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle ChemotherapyNon-Myeloid MalignanciesAnemiaNCT00110955Amgen391
已完成
3 期
A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing ChemotherapyAnemiaNCT03776032Amgen320
已完成
3 期
Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by SurgeryStomach NeoplasmsRectal NeoplasmsNCT00036400Johnson & Johnson Pharmaceutical Research & Development, L.L.C.60
已完成
3 期
Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum ChemotherapyCancerAnemiaNeoplasmNCT00270127Johnson & Johnson Pharmaceutical Research & Development, L.L.C.375